trending Market Intelligence /marketintelligence/en/news-insights/trending/FzSH_PKWGtQvINtQfJydJg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Health Sciences becomes Immunovant at closure of $395M acquisition

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Health Sciences becomes Immunovant at closure of $395M acquisition

Immunovant Inc., formerly called Health Sciences Acquisitions Corp., has closed its acquisition of Immunovant Sciences in a deal valued at about $395 million.

The merger, announced in October, makes the original Immunovant Sciences a wholly owned subsidiary of the former Health Sciences, the combined company adopting the name Immunovant.

Shareholders of Health Sciences approved the deal at a Dec. 16 meeting, and the new company will trade under the symbol IMVT on Nasdaq.

Immunovant specializes in autoimmune diseases and is developing the drug IMVT-1401 with its partner, HanAll Biopharma.